AbbVie Deal Clears 5th Humira Biosimilar To Launch In 2023
AbbVie Inc. has gotten another drugmaker to wait until 2023 to release a biosimilar of its top-selling immunosuppressant Humira, this time striking a deal with Fresenius Kabi....To view the full article, register now.
Already a subscriber? Click here to view full article